IMV Inc. to Announce Fourth Quarter and Fiscal Year 2022 Results and Host a Conference Call and Webcast on March 16, 2023
09 March 2023 - 11:05PM
Business Wire
IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company
developing a portfolio of immune-educating therapies, based on its
novel DPX platform, to treat solid and hematologic cancers, today
announced that it will hold a conference call and webcast on
Thursday, March 16, 2023, at 8:00 a.m. ET to discuss the company’s
2022 fourth quarter and fiscal year-end financial and operational
results.
Financial analysts are invited to join the conference call by
registering at this link prior the call to receive their individual
dial-in information.
Other interested parties will be able to access the live audio
webcast at this link:
https://ir.imv-inc.com/events-and-presentations. The webcast will
be recorded and will then be available on the IMV website for 30
days following the call.
About IMV
IMV Inc. is a clinical-stage immuno-oncology company advancing a
portfolio of therapies based on the Company’s immune-educating
platform, DPX®. Through a differentiated mechanism of action, the
DPX platform delivers instruction to the immune system to generate
a specific, robust, and persistent immune response. IMV’s lead
candidate, maveropepimut-S (MVP-S), delivers antigenic peptides
from survivin, a well-recognized cancer antigen commonly
overexpressed in advanced cancers. MVP-S also delivers an innate
immune activator and a universal CD4 T cell helper peptide. These
elements foster maturation of antigen presenting cells as well as
robust activation of CD8 T cell effector and memory function. MVP-S
treatment has been well tolerated and has demonstrated defined
clinical benefit in multiple cancer indications as well as the
activation of a targeted and sustained, survivin-specific
anti-tumor immune response. MVP-S is currently being evaluated in
clinical trials for hematologic and solid cancers, including
Diffuse Large B Cell Lymphoma (DLBCL) as well as ovarian, bladder
and breast cancers. IMV is also developing a second immunotherapy
leveraging the DPX immune delivery platform, DPX-SurMAGE. This
dual-targeted immunotherapy combines antigenic peptides for both
the survivin and MAGE-A9 cancer proteins to elicit immune responses
to these two distinct cancer antigens simultaneously. A Phase 1
clinical trial in bladder cancer, using MVP-S or DPX-SurMAGE, was
initiated in early 2022. For more information, visit
www.imv-inc.com and connect with us on Twitter and LinkedIn.
IMV Forward-Looking Statements
This press release contains forward-looking information under
applicable securities law. All information that addresses
activities or developments that we expect to occur in the future is
forward-looking information. Forward-looking statements use such
word as “will”, “may”, “potential”, “believe”, “expect”,
“continue”, “anticipate” and other similar terminology.
Forward-looking statements are based on the estimates and opinions
of management on the date the statements are made. In this press
release, such forward-looking statements include, but are not
limited to, statements regarding the potential and efficacy of
MVP-S, the potential impact of the VITALIZE study and timing of
availability of the ORR from the remaining stage one patients from
its Phase 2B trial, the Company’s ability to advance its
development strategy, and the prospects for its lead immunotherapy
and its other pipeline of immunotherapy candidates. IMV Inc.
assumes no responsibility to update forward-looking statements in
this press release except as required by law. These forward-looking
statements involve known and unknown risks and uncertainties, and
those risks and uncertainties include, but are not limited to,
those related to the detailed results when presented being at least
consistent with the initial results from the VITALIZE Phase 2B
trial, the Company’s priorities with MVP-S and its DPX delivery
platform, the potential for its delivery platform and the
anticipated timing of enrollment and results for its clinical trial
programs and studies as other risks detailed from time to time in
our ongoing quarterly filings and annual information form.
Investors are cautioned not to rely on these forward-looking
statements and are encouraged to read IMV’s continuous disclosure
documents, including its current annual information form, as well
as its audited annual consolidated financial statements which are
available on SEDAR at www.sedar.com and on EDGAR at
www.sec.gov/edgar.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230309005329/en/
Investor Relations & Media
Delphine Davan Senior Director, Communications
and Investor Relations IMV Inc.
O: (902) 492.1819 ext: 1049 E: ddavan@imv-inc.com
IMV (NASDAQ:IMV)
Historical Stock Chart
From May 2024 to Jun 2024
IMV (NASDAQ:IMV)
Historical Stock Chart
From Jun 2023 to Jun 2024